MYQORZO

Indicated For

obstructive hypertrophic cardiomyopathy, oHCM

About This Medication

# MYQORZO & You Patient Guide: How to Get MYQORZO (aficamten) at Low or No Cost MYQORZO (aficamten) is an FDA-approved once-daily oral medication for adults with **symptomatic obstructive hypertrophic cardiomyopathy (oHCM)**, a condition where the heart muscle thickens and obstructs blood flow, causing symptoms like shortness of breath, fatigue, and chest pain. The **MYQORZO & You** program from **Cytokinetics** provides personalized support, including free trial offers, bridge programs, and copay assistance to help eligible patients access treatment at low or no cost while navigating the required **MYQORZO REMS Program** due to risks like heart failure.[1][2][3][9] ## About MYQORZO and Obstructive HCM Obstructive hypertrophic cardiomyopathy (oHCM) affects the heart's ability to pump blood efficiently because of thickened heart muscle that blocks outflow. MYQORZO works by targeting **cardiac myosin**, a heart muscle protein, to reduce this obstruction, improve functional capacity (like exercise tolerance), and relieve symptoms. It's taken as a tablet (5 mg, 10 mg, 15 mg, or 20 mg) once daily, with dosing adjusted based on echocardiograms every 2-8 weeks to find your individualized dose. Treatment starts at 5 mg, and your doctor monitors your **left ventricular ejection fraction (LVEF)** to ensure safety.[1][4][7][9] **Important Safety Note**: MYQORZO carries a boxed warning for heart failure risk due to systolic dysfunction. It's only available through the **MYQORZO REMS Program**, requiring certified prescribers, patient enrollment, echocardiograms before starting and periodically, and dispensing only from REMS-certified specialty pharmacies. Watch for signs like shortness of breath, swelling, fatigue, or palpitations, and report them immediately.[3][4][9] ## Who Qualifies for MYQORZO & You? The program offers support for patients prescribed MYQORZO, focusing on insurance navigation and affordability. Key offerings include: - **Free Trial Offer**: One-time 30-day supply at no cost for government-insured patients (e.g., Medicare) while verifying coverage.[2][3] - **Bridge Program**: Up to 12 months free for commercially insured patients facing initial denial.[2][3] - **Copay Savings Program**: Commercially insured patients pay as little as **$5** per fill (eligibility applies).[2][5] Qualification depends on insurance type and meeting program criteria, not strictly income-based (specific FPL thresholds not detailed). A **MYQORZO Navigator** helps from enrollment through treatment, including prior authorizations, appeals, and refill reminders. Call 833-MYQORZO (833-697-6796), Monday-Friday 8 AM-8 PM ET.[1][3] ## Income Eligibility Breakdown MYQORZO & You emphasizes insurance-based eligibility over fixed income limits. No specific federal poverty level (FPL) percentages or household thresholds are published; aid targets coverage gaps. Here's a summary: | Insurance Type | Program Option | Eligibility Notes | Benefit | |---------------|----------------|-------------------|---------| | **Government (e.g., Medicare)** | Free Trial Offer | Meet requirements* | 30-day free supply during verification[2][3] | | **Commercial** | Bridge Program | Initial denial, meet requirements* | Up to 12 months free[2][3] | | **Commercial** | Copay Program | Meet requirements* | As low as $5 per fill[2][5] | *Full terms at myqorzo.com; Navigators assist with verification. Uninsured or underinsured patients should contact a Navigator for options.[1][2] ## Insurance Requirements All patients need a prescription from a REMS-certified provider. MYQORZO is dispensed only via REMS-certified specialty pharmacies (e.g., Orsini or CareMed). Government insurance qualifies for trial offers; commercial for bridge/copay. Navigators handle prior authorizations and appeals. Medicare patients may have specific pathways—confirm with your provider or Navigator.[2][3][4] ## Step-by-Step Application Process 1. **Get Prescribed**: Discuss MYQORZO with your cardiologist. They must certify in the REMS program at MYQORZOREMS.com and complete your echocardiogram and **Patient Enrollment Form**.[3][4][7] 2. **Enroll in MYQORZO & You**: Your provider submits the **Start Form** via: - Fax: 833-697-6799 - Online portal - Direct to specialty pharmacy (Orsini: 847-892-1127; CareMed: 877-542-2731)[3] 3. **Contact Navigator**: Call 833-MYQORZO for help. They'll welcome you within 1 business day, assist with benefits investigation, and enroll you in savings programs.[1][2][3] 4. **Submit Documents**: Provider handles REMS form; additional proof (e.g., insurance card) as needed via Navigator.[3][4] 5. **Pharmacy Coordination**: Prescription goes to REMS pharmacy, which ships monthly.[4] ## Timeline and Delivery - **Approval/Start**: Navigator call within 1 business day; Free Trial ships quickly for eligible patients.[2][3] - **Processing**: Varies by insurance verification (days to weeks); Bridge for denials up to 12 months.[2] - **Delivery**: Specialty pharmacy mails directly monthly after refill authorization. Expect reminders from Navigator.[3][4] - **Monitoring**: Echocardiograms 2-8 weeks after start/changes; ongoing as needed.[7] ## Alternatives if Denied or Ineligible - **Appeal with Navigator**: They assist with insurance appeals.[3] - **Other Savings**: Check Copay Program if commercial; explore manufacturer or foundation aid.[2][5] - **Clinical Alternatives**: Discuss with your doctor options like beta-blockers, calcium channel blockers, disopyramide, or mavacamten (another myosin inhibitor). Patient assistance foundations for HCM may help uninsured.[8] - **No Biosimilars**: MYQORZO has none currently.[1] ## Disclaimer This guide is for informational purposes based on available program details as of 2026. Eligibility, terms, and benefits can change—always verify with MYQORZO & You (833-MYQORZO) or myqorzo.com. Not a substitute for medical advice. Consult your healthcare provider for personalized treatment. Cytokinetics and partners do not guarantee coverage. Annual list price ~$108,400; savings vary.[1][2][3][8] (Word count: 1028)

Program information last verified: March 30, 2026